Developer: Alexion Sale Wouldn’t Stop Us
Developer Carter Winstanley said he’s confident Alexion Pharmaceuticals won’t abandon plans to move its headquarters into his new $100 million building at 100 College St., despite reports that the company may be acquired by a larger pharmaceutical firm.
If it ever did abandon plans, he’d continue with the building and find a new tenant, he said.
Winstanley made the remarks Monday following news reports that Roche Holding AG, the world’s largest producer of cancer drugs, may buy Alexion.
Click here to continue reading Melissa’s report.